Literature DB >> 29796997

Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?

M K Singh1, N Pushker1, R Meel1, K Chodsol2, S Sen1, S Bakhshi3, L Singh4, S Kashyap5.   

Abstract

PURPOSE: Uveal melanoma, although a rare form of cancer, is the most common primary malignancy of the eye in adults. Nuclear factor-κB (NF-κB) is a transcription factor that transactivates genes involved in the regulation of cell growth, apoptosis, angiogenesis, and metastasis, but the molecular mechanisms that negatively regulate NF-κB activation are not fully understood. NF-κB can also be activated by DNA damage pathway through NEMO protein. Therefore, the objective of this study is to elucidate the role of NEMO/IKKγ protein in uveal melanoma patients.
METHODS: Seventy-five formalin-fixed paraffin-embedded prospective tissues of uveal melanoma were included in the present study. These cases were reviewed and investigated for the expression of NEMO/IKKγ protein by immunohistochemistry and validated by western blotting along with the qRT-PCR for mRNA expression. Expression levels were correlated with the clinicopathological parameters and patients' outcome.
RESULTS: Immunohistochemistry showed cytoplasmic expression of NEMO/IKKγ expression in only 22 out of 75 (29.33%) cases. This result was confirmed by western blotting, and correlated well with the immunohistochemical expression of NEMO/IKKγ protein (48 kDa). In addition, downregulation of this gene was found in 87.93% of the cases when compared with the normal tissues. On statistical analysis, loss of NEMO/IKKγ protein was correlated with neovascularization, high mitotic count, and presence of vascular loop (p < 0.05). There was less overall survival rate with low expression of NEMO/IKKγ protein in patients with uveal melanoma.
CONCLUSION: This was the first study suggesting the relevant role of NEMO/IKKγ protein, and highlights the prognostic significance with outcome in uveal melanoma patients. This protein might be used as a screening biomarker in these patients after large-scale validation and translational studies.

Entities:  

Keywords:  Immunohistochemistry; NEMO protein; Prognosis validation and translational studies; Uveal melanoma; qRT-PCR

Mesh:

Substances:

Year:  2018        PMID: 29796997     DOI: 10.1007/s12094-018-1895-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

1.  Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases.

Authors:  Carol L Shields; Swathi Kaliki; Minoru Furuta; Arman Mashayekhi; Jerry A Shields
Journal:  Retina       Date:  2012-07       Impact factor: 4.256

2.  Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma.

Authors:  Ivana K Kim; Anne Marie Lane; Evangelos S Gragoudas
Journal:  Arch Ophthalmol       Date:  2010-07

Review 3.  Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas.

Authors:  Carol L Shields; Janet Manalac; Chandana Das; Kyle Ferguson; Jerry A Shields
Journal:  Curr Opin Ophthalmol       Date:  2014-05       Impact factor: 3.761

4.  Incidence of noncutaneous melanomas in the U.S.

Authors:  Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

Review 5.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients.

Authors:  Erika M Damato; Bertil E Damato
Journal:  Ophthalmology       Date:  2012-04-11       Impact factor: 12.079

7.  Population-based incidence of uveal melanoma in various races and ethnic groups.

Authors:  Dan-Ning Hu; Guo-Pei Yu; Steven A McCormick; Susan Schneider; Paul T Finger
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

8.  Effectiveness of treatments for metastatic uveal melanoma.

Authors:  James J Augsburger; Zélia M Corrêa; Adeel H Shaikh
Journal:  Am J Ophthalmol       Date:  2009-04-17       Impact factor: 5.258

9.  Combined treatment of uveal melanoma liver metastases.

Authors:  Birute Brasiuniene; V Sokolovas; V Brasiunas; A Barakauskiene; K Strupas
Journal:  Eur J Med Res       Date:  2011-02-24       Impact factor: 2.175

Review 10.  Using risk factors for detection and prognostication of uveal melanoma.

Authors:  Pukhraj Rishi; Vikram V Koundanya; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

View more
  1 in total

1.  Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Neeru Saini; Rachna Meel; Kunzang Chosdol; Sameer Bakhshi; Seema Sen; Pradeep Venkatesh; Bhavna Chawla; Jasbir Kaur; Seema Kashyap
Journal:  Clin Exp Metastasis       Date:  2019-05-08       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.